Groundbreaking clinical study recently launched to accelerate clinical development of new treatments for scleroderma Journal of Scleroderma and Related Disorders outlines protocol and rationale for two initial investigational drugs San…
Read More
Last week, the CONQUEST team had the incredible opportunity to visit Japan! 🇯🇵 CONQUEST is a global platform clinical trial created by the Scleroderma Research Foundation with input from partner...
Read More
The goal of all clinical trials is to be as inclusive as possible. However, it is necessary to develop specific inclusion and exclusion criteria. The reason for this is to...
Read More
San Francisco, CA (June 25, 2024)—CONQUEST, a highly innovative platform clinical trial conceived of and led by the Scleroderma Research Foundation (SRF) and designed to rapidly advance promising treatments for...
Read More
Here at the Scleroderma Research Foundation, research is at the center of all we do to find a cure—and that's only possible because of the dedicated support of our community....
Read More
Research is at the center of all we do here at the SRF to find a cure for scleroderma. This is why, in 2018, we launched CONQUER (COllaborative, National QUality...
Read More
Dr. Gordon will have oversight over the SRF’s global clinical trial program CONQUEST and will contribute to the research program across the SRF portfolio San Francisco, CA (January 25, 2024)…
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
• Sanofi is inaugural partner • Initial focus on Interstitial Lung Disease Secondary to Scleroderma • SRF will submit and hold the IND as the trial Sponsor SAN FRANCISCO, August...
Read More
